Synthesis and structure - Activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis

Venkatesan Aranapakam, Jamie M. Davis, George T. Grosu, Jannie Baker, John Ellingboe, Arie Zask, Jeremy I. Levin, Vincent P. Sandanayaka, Mila Du, Jerauld S. Skotnicki, John F. DiJoseph, Amy Sung, Michele A. Sharr, Loran M. Killar, Thomas Walter, Guixian Jin, Rebecca Cowling, Jeff Tillett, Weiguang Zhao, Joseph McDevittZhang Bao Xu

Research output: Contribution to journalArticlepeer-review

77 Scopus citations

Abstract

The matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases that play a key role in both physiological and pathological tissue degradation. In our preceding paper, we have reported on a series of novel and orally active N-hydroxy-α-phenylsulfonylacetamide derivatives. However, these compounds had two drawbacks (moderate selectivity and chirality issues). To circumvent these two problems, a series of novel and orally active N-substituted 4-benzenesulfonylpiperidine-4-carboxylic acid hydroxyamide derivatives have been synthesized. The present paper deals with the synthesis and SAR of these compounds. Among the several compounds synthesized, derivative 55 turned out to be a potent, selective, and an orally active MMP inhibitor in the clinically relevant advanced rabbit osteoarthritis model. Detailed pharmacokinetics and metabolism data are described.

Original languageEnglish
Pages (from-to)2376-2396
Number of pages21
JournalJournal of Medicinal Chemistry
Volume46
Issue number12
DOIs
StatePublished - Jun 5 2003
Externally publishedYes

Fingerprint

Dive into the research topics of 'Synthesis and structure - Activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis'. Together they form a unique fingerprint.

Cite this